<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">28225966</article-id>
      <article-id pub-id-type="pmc">5312188</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20174895</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Chronic tophaceous gout in patients with psoriasis<xref ref-type="fn" rid="fn1">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lobato</surname>
            <given-names>La&#xED;s Cruz</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Coutinho</surname>
            <given-names>J&#xE9;ssica Castiel</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Frota</surname>
            <given-names>Maria Zeli Moreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schettini</surname>
            <given-names>Antonio Pedro Mendes</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Santos</surname>
            <given-names>M&#xF4;nica</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
          <xref ref-type="aff" rid="aff5">5</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Private Clinic - Manaus (AM), Brazil</aff>
      <aff id="aff2"><label>2</label>Department of Mycology - School of Pharmaceutical
Sciences - Universidade Federal do Amazonas (UFAM) - Manaus (AM), Brazil</aff>
      <aff id="aff3"><label>3</label>Department of Dermatopathology - Funda&#xE7;&#xE3;o
Alfredo da Matta (FUAM) - Manaus (AM), Brazil</aff>
      <aff id="aff4"><label>4</label>Department of Psoriasis - Funda&#xE7;&#xE3;o Alfredo
da Matta (FUAM) - Manaus (AM), Brazil</aff>
      <aff id="aff5"><label>5</label>School of Medicine - Universidade do Estado do Amazonas
(UEA) - Manaus (AM), Brazil</aff>
      <author-notes>
        <corresp id="c1">Mailing address: M&#xF4;nica Santos, Rua Codaj&#xE1;s, 24,
Cachoeirinha, 69065-130 - Manaus, AM, Brazil. E-mail:
<email>m.n.souza.santos@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jan-Feb</season>
        <year>2017</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2017</year>
      </pub-date>
      <volume>92</volume>
      <issue>1</issue>
      <fpage>104</fpage>
      <lpage>106</lpage>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>7</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>1</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2017 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <copyright-year>2017</copyright-year>
        <copyright-holder>Anais Brasileiros de Dermatologia</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Psoriasis is a chronic inflammatory disease of multifactorial etiology influenced
by genetic, immunological, and environmental factors. We report the case of a
patient with psoriasis for more than 25 years who developed hyperuricemia and
chronic tophaceous gout with unusual appearance. In psoriasis, hyperuricemia may
occur by increased epidermal cell turnover, which accelerates purine metabolism
and has uric acid as the product of its catabolism. The association of psoriasis
with hyperuricemia can trigger the onset of gouty arthritis, and pose a greater
risk of developing other inflammatory comorbidities. Therefore, it is important
to periodically investigate uric acid levels in order to treat changes triggered
by hyperuricemia.</p>
      </abstract>
      <kwd-group>
        <kwd>Gout</kwd>
        <kwd>Psoriasis</kwd>
        <kwd>Uric acid</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Psoriasis is a chronic inflammatory disease that can affect the skin, joints, nails,
and scalp. It has a multifactorial etiology, with the participation of genetic,
immunological, and environmental factors. Several studies have demonstrated the role
of inflammatory cells and mediators in its pathogenesis. It is defined as a systemic
and immune-mediated inflammatory disease, which can be associated with other
inflammatory diseases.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref></sup> One of these diseases is gout, a
disorder caused by the deposition of urate crystals in joints and periarticular
tissues. Its basic feature is hyperuricemia. It is defined by serum uric acid levels
above 6.8 mg/dl (404 nmol/L), which is the approximate saturation point of urate
solubility under physiological conditions of temperature and pH.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> Uric acid levels beyond blood
solubility may form crystals, and consequently, gouty arthritis. This is a
potentially destructive disease that not only deposits crystals within the joints
and skin, but can also stimulate inflammatory cytokines and chemotactic factors for
neutrophils.<sup><xref rid="r4" ref-type="bibr">4</xref></sup> We report the
case of a patient with psoriasis for more than 25 years who developed hyperuricemia
and unsightly gouty tophus formation.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>We report a 47-year-old male patient who had psoriasis since he was 19. In 2013, he
also reported pain and edema in the right knee joints and right elbow, interpreted
as psoriatic arthritis, for which he received classical systemic treatment with
methotrexate. The cutaneous and joint manifestations evolved with partial
improvement, and the patient stopped treatment for two years. He returned to
dermatologic consultation with small erythematous scaly papules on the upper and
lower limbs, and erythema and flaky scalp. However, his main complaint at that time
was pain, volume increase, and severely swollen softened lesion on the side of the
left foot, with a 6-month period evolution (<xref ref-type="fig" rid="f1">Figure
1</xref>). Based on the clinical picture, we suspected of mycetoma,
phaeohyphomycosis, atypical mycobacteriosis, septic arthritis, and gout tophaceous.
The following tests were performed: complete blood count, blood glucose dosage,
lipid profile, foot radiography, renal ultrasound, and skin biopsy. The material was
sent to histopathological and mycological examinations. Seven days after biopsy, the
lesion evolved with fistula formation and drainage of yellow-white exudate and lumpy
material (<xref ref-type="fig" rid="f2">Figure 2</xref>). Histological examination
with hematoxylin-eosin showed hyperkeratosis and acanthosis in the epidermis. The
dermis revealed thickened collagen with infiltration of mononuclear cells around the
vessels and the presence of amorphous material, with a lightly eosinophilic
appearance, surrounded by coarse bands of collagen tissue (<xref ref-type="fig" rid="f3">Figure 3</xref>). Staining with periodic acid-Schiff (PAS) showed no
fungal structures. The direct examination of the lumpy material sent to medical
mycology laboratory showed the presence of spiculated structures compatible with
crystal deposits (<xref ref-type="fig" rid="f4">Figure 4</xref>). There was no
fungal growth in the culture medium. Serum levels were the following: uric acid
(10.8 mg/dl); glucose (119 mg/dL); total cholesterol (256 mg/dL); and HDL (36
mg/dL). The concentration of uric acid in the 24-hour urine specimen was 1.450 mg/dL
(reference value up to 750 mg/dL). No renal calculi were detected in kidney
ultrasound. Left foot radiograph (dorsoplantar view) showed erosion and sclerosis of
the forefoot bones, with preservation of joint spaces and bone density. Based on
clinical and laboratory findings, the diagnosis of chronic tophaceous gout was
confirmed. The patient was then sent to a concomitant rheumatologist follow-up,
which started treatment with colchicine (0.5 mg every 12 hours orally). Allopurinol
(300 mg orally) was added to the treatment 14 days later. Two months after the
introduction of medications, we observed a normalization of uric acid concentration
and a significant reduction of the gouty tophus lesion and pain. The patient has
been followed at dermatology and reumatology clinical setting.</p>
      <p>
        <fig id="f1" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Severely swollen and softened lesion on the side of the left foot with a
6-month period evolution</p>
          </caption>
          <graphic xlink:href="abd-92-01-0104-gf01"/>
        </fig>
      </p>
      <p>
        <fig id="f2" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Seven days after biopsy, the lesion evolved with fistula formation and
drainage of yellow-white exudate and lumpy material</p>
          </caption>
          <graphic xlink:href="abd-92-01-0104-gf02"/>
        </fig>
      </p>
      <p>
        <fig id="f3" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Histological examination with hematoxylin-eosin showed hyperkeratosis and
acanthosis in the epidermis. The dermis revealed thickened collagen with
infiltration of mononuclear cells around the vessels and the presence of
amorphous material, with a lightly eosinophilic appearance, surrounded
by coarse bands of collagen tissue</p>
          </caption>
          <graphic xlink:href="abd-92-01-0104-gf03"/>
        </fig>
      </p>
      <p>
        <fig id="f4" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <p>The direct examination of the lumpy material sent to medical mycology
laboratory showed the presence of spiculated structures compatible with
crystal deposits</p>
          </caption>
          <graphic xlink:href="abd-92-01-0104-gf04"/>
        </fig>
      </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>In psoriasis, hyperuricemia may occur by increased epidermal cell turnover, which
accelerates purine metabolism and has uric acid as the product of its catabolism.
Other factors also contribute to this hyperuricemia, such as alcohol consumption -
especially fermented drinks - genetic predisposition, and metabolic syndrome
coexistence. In our case, the patient used alcohol regularly and had a diagnosis of
metabolic syndrome. Differential diagnosis of gouty arthritis include septic
psoriatic, and rheumatoid arthritis.<sup><xref rid="r5" ref-type="bibr">5</xref></sup> In the reported case, the involvement of soft tissue with edema
and elimination of lumpy material raised the suspicion of mycetoma and
mycobacteriosis. In the acute phase of chronic tophaceous gout, conventional
radiography may reveal swelling of soft tissue and joint effusion. In the chronic
phase, intra-articular or para-articular erosions bounded by sclerotic borders can
be identified, as well as osteophytes partially covering the tophi. The joint space
is well preserved up to the advanced stage of the disease. No osteopenia is
observed, which is common in other forms of arthritis.<sup><xref rid="r6" ref-type="bibr">6</xref></sup> The increase in uric acid level may also contribute
to the onset of inflammatory systemic comorbidities, and be associated with more
severe cases of psoriasis. Gisondi <italic>et al.</italic> compared uric acid levels
of individuals with psoriasis and control groups matched by age, sex, and body mass
index. They found significantly higher values in patients with psoriasis. By
logistic regression analysis, the authors also concluded that psoriasis was the
strongest predictor of hyperuricemia in the studied population, after adjustment for
age, sex, and components of the metabolic syndrome.<sup><xref rid="r7" ref-type="bibr">7</xref></sup> In another study, Kown <italic>et al.</italic>
correlated hyperuricemia with a greater severity of the disease and with higher PASI
(Psoriasis Area Severity Index) scores.<sup><xref rid="r8" ref-type="bibr">8</xref></sup> In 2011, Isha <italic>et al.</italic> investigated the levels of
uric acid in 24 patients before and 12 weeks after the treatment of psoriasis. They
demonstrated statistically significant decreased levels of uric acid in the blood of
patients with improvement in psoriasis clinical picture.<sup><xref rid="r9" ref-type="bibr">9</xref></sup> The association of psoriasis with hyperuricemia can
trigger the onset of gouty arthritis and disabling pain, and pose a greater risk of
developing other inflammatory comorbidities, especially cardiovascular. Thus,
periodic investigation of uric acid levels and consequent early treatment of
alterations triggered by hyperuricemia are essential.<sup><xref rid="r10" ref-type="bibr">10</xref></sup></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>Conflict of Interest: None</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None</p>
      </fn>
      <fn fn-type="other" id="fn1">
        <label>*</label>
        <p>Work performed at Funda&#xE7;&#xE3;o Alfredo da Matta (UAM) - Manaus (AM),
Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Voiculescu</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Lupu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Papagheorghe</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Giurcaneanu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Micu</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Psoriasis and Metabolic Syndrome-scientific evidence and
therapeutic implications</article-title>
          <source>J Med Life</source>
          <year>2014</year>
          <volume>7</volume>
          <fpage>468</fpage>
          <lpage>471</lpage>
          <pub-id pub-id-type="pmid">25713604</pub-id>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Jalkh</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Cavalcante Ade</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Obesity and dyslipidemia in patients with psoriasis treated at a
dermatologic clinic in Manaus</article-title>
          <source>An Bras Dermatol</source>
          <year>2013</year>
          <volume>88</volume>
          <fpage>913</fpage>
          <lpage>916</lpage>
          <pub-id pub-id-type="pmid">24474099</pub-id>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Xiao</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>HD</given-names>
            </name>
          </person-group>
          <article-title>Coexisting gout, erythrodermic psoriasis and psoriatic
arthritis</article-title>
          <source>Eur J Dermatol</source>
          <year>2009</year>
          <volume>19</volume>
          <fpage>184</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="pmid">19106055</pub-id>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Punzi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Scanu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ramonda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Oliviero</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Gout as autoinflammatory disease: new mechanisms for more
appropriated treatment targets</article-title>
          <source>Autoimmun Rev</source>
          <year>2012</year>
          <volume>12</volume>
          <fpage>66</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="pmid">22884557</pub-id>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chandra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Senapati</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chatterjee</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Genetic and epigenetic basis of psoriasis
pathogenesis</article-title>
          <source>Mol Immunol</source>
          <year>2015</year>
          <volume>64</volume>
          <fpage>313</fpage>
          <lpage>323</lpage>
          <pub-id pub-id-type="pmid">25594889</pub-id>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuo</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Grainge</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Mallen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Doherty</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Comorbidities in patients with gout prior to and following
diagnosis: case-control study</article-title>
          <source>Ann Rheum Dis</source>
          <year>2016</year>
          <volume>75</volume>
          <fpage>210</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="pmid">25398375</pub-id>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gisondi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Targher</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cagalli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Girolomoni</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Hyperuricemia in patients with chronic plaque
psoriasis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2014</year>
          <volume>70</volume>
          <fpage>127</fpage>
          <lpage>130</lpage>
          <pub-id pub-id-type="pmid">24183485</pub-id>
        </element-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kwon</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Kwon</surname>
              <given-names>IH</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Youn</surname>
              <given-names>JI</given-names>
            </name>
          </person-group>
          <article-title>Cross-sectional study on the correlation of serum uric acid with
disease severity in Korean patients with psoriasis</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2011</year>
          <volume>36</volume>
          <fpage>473</fpage>
          <lpage>478</lpage>
          <pub-id pub-id-type="pmid">21679368</pub-id>
        </element-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Isha</surname>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Lal</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>C-reactive protein and uric acid levels in patients with
psoriasis</article-title>
          <source>Indian J Clin Biochem</source>
          <year>2011</year>
          <volume>26</volume>
          <fpage>309</fpage>
          <lpage>311</lpage>
          <pub-id pub-id-type="pmid">22754198</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feig</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Uric acid and cardiovascular risk</article-title>
          <source>N Engl J Med</source>
          <year>2008</year>
          <volume>359</volume>
          <fpage>1811</fpage>
          <lpage>1821</lpage>
          <pub-id pub-id-type="pmid">18946066</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
